Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Balance Sheet
Balance Sheet Decomposition
Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Balance Sheet
Recursion Pharmaceuticals Inc
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
70
|
262
|
285
|
550
|
392
|
594
|
|
| Cash Equivalents |
70
|
262
|
285
|
550
|
392
|
594
|
|
| Short-Term Investments |
0
|
0
|
231
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
9
|
3
|
3
|
49
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
9
|
3
|
0
|
0
|
|
| Other Current Assets |
6
|
4
|
9
|
17
|
43
|
71
|
|
| Total Current Assets |
76
|
266
|
535
|
570
|
438
|
714
|
|
| PP&E Net |
24
|
26
|
65
|
121
|
120
|
233
|
|
| PP&E Gross |
24
|
26
|
65
|
121
|
120
|
233
|
|
| Accumulated Depreciation |
6
|
10
|
19
|
30
|
45
|
63
|
|
| Intangible Assets |
0
|
2
|
1
|
1
|
36
|
336
|
|
| Goodwill |
0
|
1
|
1
|
1
|
52
|
149
|
|
| Other Long-Term Assets |
1
|
4
|
9
|
8
|
7
|
16
|
|
| Other Assets |
0
|
1
|
1
|
1
|
52
|
149
|
|
| Total Assets |
101
N/A
|
299
+194%
|
610
+104%
|
701
+15%
|
654
-7%
|
1 449
+122%
|
|
| Liabilities | |||||||
| Accounts Payable |
1
|
1
|
3
|
5
|
4
|
22
|
|
| Accrued Liabilities |
5
|
11
|
34
|
39
|
53
|
94
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
0
|
0
|
0
|
8
|
|
| Other Current Liabilities |
0
|
10
|
10
|
57
|
36
|
63
|
|
| Total Current Liabilities |
7
|
23
|
47
|
100
|
93
|
187
|
|
| Long-Term Debt |
12
|
11
|
1
|
1
|
1
|
19
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
1
|
17
|
|
| Other Liabilities |
6
|
22
|
20
|
115
|
95
|
191
|
|
| Total Liabilities |
25
N/A
|
57
+130%
|
67
+19%
|
216
+220%
|
190
-12%
|
414
+117%
|
|
| Equity | |||||||
| Common Stock |
201
|
448
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
127
|
214
|
400
|
640
|
968
|
1 431
|
|
| Additional Paid In Capital |
2
|
7
|
943
|
1 125
|
1 431
|
2 474
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
8
|
|
| Total Equity |
77
N/A
|
242
+215%
|
543
+124%
|
486
-11%
|
463
-5%
|
1 035
+123%
|
|
| Total Liabilities & Equity |
101
N/A
|
299
+194%
|
610
+104%
|
701
+15%
|
654
-7%
|
1 449
+122%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
162
|
162
|
170
|
191
|
234
|
397
|
|